NCT02787369 2026-01-07ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLLDana-Farber Cancer InstitutePhase 1 Active not recruiting3 enrolled
NCT02457598 2025-06-17Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell MalignanciesGilead SciencesPhase 1 Terminated203 enrolled 43 charts